DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n6p79b/countryfocus) has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Israel" report to their offering.
During the 2008-2013 period, the Israeli pharmaceutical market increased at a Compound Annual Growth Rate (CAGR) at 3.0%. It was worth $1.7 billion in 2008, and is projected to reach approximately $2.3 billion by 2020 at a CAGR of 2.8% (AESGP, 2013).
Technological advances in the medical field, high expenditure on research and development and a robust economy provide the building blocks for the growth of the Israeli pharmaceutical market
The pharmaceutical sector is the largest and most established sector of the Israeli life science industry. It has a total of 76 companies, with 22% involved in drug discovery and 17% in drug delivery. Israel is one of the major markets in terms of healthcare and pharmaceuticals in the Middle East. It is also the location of the headquarters of Teva Pharmaceuticals, which is one of the largest manufacturers and exporters of generic pharmaceuticals and Active Pharmaceutical Ingredients (APIs) in the world.
R&D expenditure in the field of science and technology and medical technological advances are the distinguishing features of the Israeli pharmaceutical market. According to the US Patent and Trademark Office, Israel has the highest number of registered medical device patents per capita in the world, which includes innovations such as ingestible cameras, portable cardiac ultrasound systems, implantable visual aids for the sight-impaired, and instant CT Scanners (USPTO, 2009). Gross Domestic Product (GDP) expenditure on R&D in science in 2008 was $8.77 billion, and increased to an estimated $9.12 billion in 2013 (OECD, 2014).
Israel also ranks among the world's leading countries in terms of number of scientists, engineers and high-tech start-ups per capita, as well as in R&D spending per capita.
The medical device market was worth approximately $1.3 billion in 2013, and is expected to grow to approximately $1.8 billion by 2020, at a CAGR of 5.0%. In terms of market share, the main segments in 2013 were cardiovascular with 12.9%, nephrology and urology devices with 12.1%, and vitro diagnostics with 10.6%. The medical care and diagnostic markets are expected to see strong growth in the future due to increasing awareness of chronic diseases.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Overview of the Pharmaceutical and Medical Device Markets
- Pharmaceutical Market
- Medical Device Market
- Market Drivers and Barriers
4 Market Access
- Reimbursement and Payer Landscape
- Regulatory Landscape
5 Country Analysis
- Political Environment
- Economic Landscape
- Economic Indicators
- Demographics
- Healthcare Infrastructure
- Healthcare Expenditure
- Trade Associations
- Trade Fairs
6 Opportunities and Challenges
7 Appendix
For more information visit http://www.researchandmarkets.com/research/n6p79b/countryfocus
